Published in Stroke on September 01, 2005
Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol (2013) 4.29
Staging and natural history of cerebrovascular pathology in dementia. Neurology (2012) 2.61
Structural brain changes in migraine. JAMA (2012) 2.47
Blood pressure and white-matter disease progression in a biethnic cohort: Atherosclerosis Risk in Communities (ARIC) study. Stroke (2009) 1.70
Small Brain Lesions and Incident Stroke and Mortality: A Cohort Study. Ann Intern Med (2015) 1.49
Retinal microvascular abnormalities and cognitive decline: the ARIC 14-year follow-up study. Neurology (2009) 1.40
Cerebrovascular disease, β-amyloid, and cognition in aging. Neurobiol Aging (2011) 1.37
Diabetic retinopathy and cognitive decline in older people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes (2010) 1.32
Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. J Neurol Neurosurg Psychiatry (2007) 1.17
The overlap between vascular disease and Alzheimer's disease--lessons from pathology. BMC Med (2014) 1.15
Corpus callosum atrophy is associated with mental slowing and executive deficits in subjects with age-related white matter hyperintensities: the LADIS Study. J Neurol Neurosurg Psychiatry (2006) 1.12
Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: the LADIS study. J Neurol (2006) 1.10
Association between subcortical vascular lesion location and cognition: a voxel-based and tract-based lesion-symptom mapping study. The SMART-MR study. PLoS One (2013) 1.09
Automatic segmentation of white matter hyperintensities in the elderly using FLAIR images at 3T. J Magn Reson Imaging (2010) 1.07
Vascular imaging abnormalities and cognition: mediation by cortical volume in nondemented individuals: atherosclerosis risk in communities-neurocognitive study. Stroke (2015) 1.07
Brain atrophy associations with white matter lesions in the ageing brain: the Lothian Birth Cohort 1936. Eur Radiol (2012) 1.05
New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters? J Headache Pain (2013) 1.02
Brain vascular disease overt and covert. Stroke (2005) 1.01
Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies. J Alzheimers Dis (2008) 0.95
The impact of vascular burden on late-life depression. Brain Res Rev (2009) 0.94
Age-related white matter changes. J Aging Res (2011) 0.93
Longitudinal follow-up of individual white matter hyperintensities in a large cohort of elderly. Neuroradiology (2009) 0.92
Single and combined effects of cerebral white matter lesions and lacunar infarctions on cognitive function in an elderly population. J Gerontol A Biol Sci Med Sci (2009) 0.91
Total MRI load of cerebral small vessel disease and cognitive ability in older people. Neurobiol Aging (2015) 0.91
Influences of lobar gray matter and white matter lesion load on cognition and mood. Psychiatry Res (2010) 0.89
Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats. Am J Hypertens (2010) 0.89
Discriminating between silent cerebral infarction and deep white matter hyperintensity using combinations of three types of magnetic resonance images: a multicenter observer performance study. Neuroradiology (2008) 0.86
Appraisal of cognition in preclinical Alzheimer's disease: a conceptual review. Neurodegener Dis Manag (2012) 0.85
Association of white matter hyperintensities and gray matter volume with cognition in older individuals without cognitive impairment. Brain Struct Funct (2015) 0.83
Pathological correlates of white matter hyperintensities on magnetic resonance imaging. Dement Geriatr Cogn Disord (2014) 0.82
An MRI-based semiquantitative index for the evaluation of brain atrophy and lesions in Alzheimer's disease, mild cognitive impairment and normal aging. Dement Geriatr Cogn Disord (2010) 0.82
Cerebral white matter disease is associated with Alzheimer pathology in a prospective cohort. Alzheimers Dement (2012) 0.82
Brain health: the importance of recognizing cognitive impairment: an IAGG consensus conference. J Am Med Dir Assoc (2015) 0.82
Magnetization transfer ratio relates to cognitive impairment in normal elderly. Front Aging Neurosci (2014) 0.80
Cerebral microbleeds are associated with worse cognitive function in the nondemented elderly with small vessel disease. Cerebrovasc Dis Extra (2014) 0.79
Shape abnormalities of the caudate nucleus correlate with poorer gait and balance: results from a subset of the LADIS study. Am J Geriatr Psychiatry (2013) 0.78
Effect of hypertension and carotid occlusion on brain parenchymal arteriole structure and reactivity. J Appl Physiol (1985) (2015) 0.78
Relationships between 24-Hour Blood Pressures, Subcortical Ischemic Lesions, and Cognitive Impairment. J Clin Neurol (2009) 0.78
Total Cerebral Small Vessel Disease MRI Score Is Associated with Cognitive Decline in Executive Function in Patients with Hypertension. Front Aging Neurosci (2016) 0.78
Progression of White Matter Lesion Volume and Health-Related Quality of Life in Patients with Symptomatic Atherosclerotic Disease: The SMART-MR Study. J Aging Res (2011) 0.78
MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. Front Aging Neurosci (2017) 0.78
Silent New Brain Lesions: Innocent Bystander or Guilty Party? J Stroke (2015) 0.77
Vascular risk and FDDNP-PET influence cognitive performance. J Alzheimers Dis (2013) 0.77
Cerebral Small Vessel Disease: Targeting Oxidative Stress as a Novel Therapeutic Strategy? Front Pharmacol (2016) 0.76
The Association between Cerebral White Matter Lesions and Plasma Omega-3 to Omega-6 Polyunsaturated Fatty Acids Ratio to Cognitive Impairment Development. Biomed Res Int (2015) 0.75
Association between changes in brain microstructure and cognition in older subjects at increased risk for vascular disease. BMC Neurol (2015) 0.75
Sleep Disordered Breathing and White Matter Hyperintensities in Community-Dwelling Elders. Sleep (2016) 0.75
Relationship Between White Matter Hyperintensities Penumbra and Cavity Formation. Med Sci Monit (2016) 0.75
Leukoaraiosis rather than lacunes predict poor outcome and chest infection in acute ischemic stroke patients. Int J Clin Exp Med (2015) 0.75
Effects of exercise on capillaries in the white matter of transgenic AD mice. Oncotarget (2017) 0.75
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
Mild cognitive impairment. Lancet (2006) 10.21
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol (2006) 6.97
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol (2013) 6.18
MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol (2012) 5.91
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Further Implications of Off-Label Use of Acetazolamide in the Management of Moyamoya Disease in Japan: Response. Radiology (2017) 4.99
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59
Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp (2005) 4.11
PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med (2013) 4.02
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol (2012) 3.93
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (2011) 3.76
Vascular cognitive impairment. Lancet Neurol (2003) 3.73
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40
Subcortical ischaemic vascular dementia. Lancet Neurol (2002) 3.32
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol (2007) 3.22
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: data from a multicenter multinational hospital-based registry. Stroke (2003) 3.15
Fast and robust multi-atlas segmentation of brain magnetic resonance images. Neuroimage (2009) 3.13
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke (2008) 2.57
Cognitive impairment in heart failure: a systematic review of the literature. Eur J Heart Fail (2006) 2.56
Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology (2005) 2.47
Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry (2010) 2.44
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
Profile of cognitive impairment in chronic heart failure. J Am Geriatr Soc (2007) 2.43
Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension (2004) 2.43
Brain imaging in patients with diabetes: a systematic review. Diabetes Care (2006) 2.39
Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol (2011) 2.37
Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem (2009) 2.32
Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol (2010) 2.31
Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project. Stroke (2003) 2.31
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain (2002) 2.30
White matter lesion progression, brain atrophy, and cognitive decline: the Austrian stroke prevention study. Ann Neurol (2005) 2.29
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging (2010) 2.27
Carotid artery stenting: first consensus document of the ICCS-SPREAD Joint Committee. Stroke (2006) 2.21
Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain (2003) 2.20
Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol (2012) 2.19
Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain (2010) 2.19
Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele. Lancet Neurol (2010) 2.18
Diffusion tensor imaging using single-shot SENSE-EPI. Magn Reson Med (2002) 2.14
Loss of 'small-world' networks in Alzheimer's disease: graph analysis of FMRI resting-state functional connectivity. PLoS One (2010) 2.12
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol (2005) 2.10
Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA (2009) 2.10
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol (2005) 2.07
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler (2011) 2.07
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology (2004) 2.00
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement (2013) 1.98
Advances in the early detection of Alzheimer's disease. Nat Med (2004) 1.97
Grey matter pathology in multiple sclerosis. Lancet Neurol (2008) 1.97
Acute unilateral hearing loss as an early symptom of lateral cerebral sinus venous thrombosis. Arch Neurol (2012) 1.97
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet (2004) 1.93
Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nat Genet (2011) 1.92
Impact of age-related cerebral white matter changes on the transition to disability -- the LADIS study: rationale, design and methodology. Neuroepidemiology (2005) 1.92